These include trials investigating the incorporation of anti‐HIV genes into donor HSCs using lentiviral vectors to make transplanted cells resistant to HIV infection in HIV‐related lymphoma (e.g., NCT01961063, NCT02337985, NCT02797470) and trials using the CRISPR‐Cas9 technology to knockout the CD33 gene in HSCs to make them resistant to anti‐CD33 drug treatment in acute myeloid leukemia (e.g., NCT05662904, NCT04849910). This evidence concerns the gene CD33 and lymphoma.